Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Modular PMA goals: FDA should complete review of 70% of PMA modules within 90 days, starting in fiscal 2006, AdvaMed proposes in Jan. 7 comments to FDA. Under the plan, 80% of modules would be completed in 90 days in 2007. AdvaMed's review performance targets differ from two proposals FDA offered at a November MDUFMA stakeholder meeting (1"The Gray Sheet" Nov. 29, 2004, p. 4). Under one agency option, 70% of modules would be completed within 120 days in 2006, rising to 80% in 2007. The alternative pledged 50% in 90 days in 2006, increasing to 60% in 2007. FDA's proposals "simply codify current performance levels, which have declined since the passage of MDUFMA," AdvaMed protests in its comments to FDA. Maintaining that user fees provide for additional review resources and that Congress has fully funded FDA for FY 2005 as required by MDUFMA, AdvaMed contends that its proposed targets for the agency are "reasonable and represent appropriate incremental improvement over current review performance"...
You may also be interested in...
Growing Concerns With Cybersecurity Hacks of Devices
While the agency released its first guidance on cybersecurity requirements a decade ago, a top FDA official says the agency has seen a spike in potential vulnerabilities over the past year and a half, and has been working with manufacturers and other stakeholders to fix them before someone gets hurt.
Hacking Of Wireless Devices Poses Growing Threat, Warns Homeland Security Report
Department of Homeland Security bulletin details the risks of "malicious intrusion" into wireless health care networks and connected medical devices.
AdvaMed Annual Submissions Workshop In Brief
Pediatric working group: Nominations are solicited for a CDRH team to facilitate pediatric premarket review consultations, coordinate activities and keep FDA's Office of Pediatric Therapeutics informed of device-related issues, Associate Director of Clinical Research & Government Affairs Joanne Less tells AdvaMed submissions workshop attendees in Arlington, Va. May 24. One staffer from each Office of Device Evaluation review branch, two from the Office of In Vitro Diagnostic Device Evaluation & Safety, and one from each of the other CDRH offices will be represented on the team...